Clinical data | |
---|---|
Trade names | Ultiva |
Other names | methyl 1-(2-methoxycarbonylethyl)-4-(phenyl-propanoyl-amino)-piperidine-4-carboxylate |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 0 |
Protein binding | 70% (bound to plasma proteins) |
Metabolism | cleaved by non-specific plasma and tissue esterases |
Elimination half-life | 1-20 minutes |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.211.201 |
Chemical and physical data | |
Formula | C20H28N2O5 |
Molar mass | 376.453 g·mol−1 |
3D model (JSmol) | |
Melting point | 5 °C (41 °F) |
| |
| |
(verify) |
Remifentanil, marketed under the brand name Ultiva is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high-dose opioid and low-dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.